Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVIDENCE kidney transplant immunosuppression regimen study
2008-007507-83Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2009
- Modality
- Small Molecules, Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of everolimus, cyclosporine, basiliximab and corticosteroids in kidney transplant immunosuppression (3 arms), sponsored by Novartis. Primary endpoint: Treatment failure rate from randomization to Month 12. Started Mar 2009; status: completed.
02
Drugs
everolimuscyclosporinebasiliximabcorticosteroids
03
Conditions
kidney transplant immunosuppression
Beyond the preview
Go deeper on 2008-007507-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007507-83.